Addimmune
Private Company
Funding information not available
Overview
Addimmune, a project within American Gene Technologies, is a clinical-stage biotechnology company focused on developing a one-time functional cure for HIV using a proprietary lentiviral gene therapy platform. Its lead candidate, AGT103-T, is designed to modify a patient's own CD4+ T cells to resist HIV infection and enhance immune control, with initial clinical trials showing promising safety and efficacy signals. The company operates as a private, pre-revenue entity, relying on funding from its parent company and donations to advance its pivotal clinical program aimed at addressing a significant unmet medical need.
Technology Platform
Lentiviral vector-based gene and cell therapy platform for ex vivo modification of CD4+ T cells to disrupt CCR5 expression and introduce anti-HIV genes, aiming to create an HIV-resistant immune system.
Opportunities
Risk Factors
Competitive Landscape
Addimmune competes in the HIV cure space with other gene therapy approaches (e.g., Sangamo/GSK's zinc finger nucleases, CRISPR-based therapies) and immunologic strategies (e.g., broadly neutralizing antibodies, therapeutic vaccines). Its differentiated lentiviral platform and multi-gene approach must demonstrate superior efficacy and safety to gain a competitive edge.